Caxton Associates LLP Biocryst Pharmaceuticals Inc Transaction History
Caxton Associates LLP
- $4.11 Billion
- Q3 2025
A detailed history of Caxton Associates LLP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Caxton Associates LLP holds 15,712 shares of BCRX stock, worth $111,240. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,712
Previous 28,379
44.64%
Holding current value
$111,240
Previous $254 Million
99.95%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding BCRX
# of Institutions
310Shares Held
200MCall Options Held
640KPut Options Held
507K-
Vanguard Group Inc Valley Forge, PA21.8MShares$154 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$141 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY12.2MShares$86.2 Million1.72% of portfolio
-
State Street Corp Boston, MA9.81MShares$69.4 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.39MShares$66.5 Million6.02% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.32B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...